Euralis Semences strengthens its financial resources to accelerate its international development

Euralis Semences carried out a capital increase of € 20 million, subscribed exclusively and equally by its historic minority shareholders, Unigrains and Sofiprotéol.

Subsidiary of the Euralis cooperative group, Euralis Semences, one of the most important seed companies in Europe, positions itself on the 3 activities of the profession:
    - research and development of new seed varieties,
    - their production,
    - their marketing.

With a consolidated turnover of 210 M €, Euralis Semences employs 1,390 people and has 12 research stations and more than 500,000 plots. Due to its European dimension and the wealth of its genetic expertise, Euralis Semences occupies a leading position in corn, sunflower, rapeseed, soybeans and sorghum seeds.

The strengthening of its equity will contribute to the construction of a seed production plant in Russia, and to the acceleration of its international development through its merger project with Caussade Semences. This consolidation would significantly strengthen the Group's position in Europe by offering a wider range of products and varieties recognized by farmers and distributors.

François-Xavier Masson, Director of Investments at Unigrains, says: “Financial partner of Euralis Semences for over 30 years, we are pleased to support the Group in this important new industrial project giving simplified access to the Russian market and presenting attractive growth opportunities. "

Luc Ozanne, Director of Investments at Sofiprotéol, says: “Seed expert for more than 60 years, Euralis Semences is distinguished by its capacity for innovation, its international development strategy and its marketing expertise focused on close proximity to distributors and farmers. We are delighted to participate in this new structuring step through which Euralis Semences is giving itself the means to create a major European player.

Philippe Saux, Managing Director at Euralis, says: “By our side since the creation of Euralis Semences, we are pleased to be able to count on the strategic and financial support of Unigrains and Sofiprotéol in the context of this new industrial project headlight. This investment will support the commercial development of Euralis Semences, which is already well established in Russia and will achieve our objective of increasing from 500,000 doses sold in the country today to 1 million doses in 2025. "

Editor's note: This article was originally published in French. This English summary has been prepared with Google Translate and edited for clarity.